Condition: Locally Advanced Urothelial Carcinoma · Oligo-metastaic Urothelial Carcinoma · Sponsor: Yale University
This study investigates the therapeutic benefit of consolidative local therapy with extirpative surgery for participants with locally advanced or oligo-metastatic urothelial carcinoma that have disease control with enfortumab vedotin-based systemic therapy and surgically resectable or previously radiated metastatic sites.
This description comes directly from the study's public registry record.
Laura Kane · 7733696904 · laura.kane@yale.edu
Always discuss trial participation with your own doctor first.
| Yale University | New Haven, Connecticut, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07048457